Nature Medicine, Published online: 06 October 2025; doi:10.1038/s41591-025-03971-6
In the double-blind, placebo-controlled phase 2 ARGO trial, patients with active psoriatic arthritis treated with a nanobody targeting IL-17A and IL-17F showed substantially better disease response rates compared with those receiving placebo treatment.
